Skip to main content
1151 search results for:

Paroxysmal Nocturnal Hemoglobinuria 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 10-05-2024 | Paroxysmal Nocturnal Hemoglobinuria | Online First

    Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease characterized by chronic complement-mediated hemolysis, thrombosis, bone marrow failure, and fatigue that impairs patients’ quality of life (QoL) [ 1 , 2 ]. It …

  2. 15-04-2024 | Paroxysmal Nocturnal Hemoglobinuria | OriginalPaper

    Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes

    Glycosylphosphatidylinositol-anchored protein-deficient hematopoietic stem and progenitor cell development caused by PIGA mutations cannot fully explain the pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH). Herein, patients newly …

  3. Open Access 01-12-2024 | Paroxysmal Nocturnal Hemoglobinuria | OriginalPaper

    Health-related quality of life and influencing factors of patients with paroxysmal nocturnal hemoglobinuria in China

    Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder, resulting from a somatic mutation in the X-linked gene phosphatidylinositol glycan class A (PIGA) which leads to the expansion of hematopoietic stem cell …

  4. Open Access 08-03-2024 | Paroxysmal Nocturnal Hemoglobinuria | Online First

    Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan

    Pegcetacoplan (Aspaveli®/Empaveli™) is a factor C3 inhibitor that is approved for the treatment of paroxysmal nocturnal hemoglobinuria. An individualized dosing strategy might be useful to improve patient-friendliness and cost-effectiveness of …

  5. Open Access 19-01-2024 | Paroxysmal Nocturnal Hemoglobinuria | OriginalPaper

    Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening blood disorder characterized by hemolysis and resulting in anemia and fatigue. Current therapies for PNH in Japan rely on complement inhibitors targeting the C5 …

  6. Open Access 24-11-2023 | Paroxysmal Nocturnal Hemoglobinuria | OriginalPaper

    Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder characterized by the specific degradation of blood cells that become vulnerable to complement-mediated hemolysis [ 1 , 2 ]. While the exact prevalence of this rare disease …

  7. Open Access 07-10-2023 | Paroxysmal Nocturnal Hemoglobinuria | OriginalPaper

    Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria

    Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled terminal complement activation leading to intravascular hemolysis (IVH), thrombosis, and impairments in quality of life (QoL). The aim of this study was to identify the …

  8. Open Access 14-09-2023 | Paroxysmal Nocturnal Hemoglobinuria | Report

    Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by continuous complement activation leading to hemolysis, chronic symptoms of anemia, fatigue, and hemoglobinuria, and life-threatening thrombosis [ 1 …

  9. Open Access 04-10-2023 | Paroxysmal Nocturnal Hemoglobinuria | Erratum

    Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison

  10. 20-06-2023 | Paroxysmal Nocturnal Hemoglobinuria | Letter

    Paroxysmal nocturnal hemoglobinuria with ulcerative colitis

  11. Open Access 01-12-2022 | Craniotomy | OriginalPaper

    Subacute stent thrombosis with spontaneously resolved secondary thrombi in paroxysmal nocturnal hemoglobinuria: a case report

    Stent thrombosis (ST) is a fatal complication associated with a mortality rate of 5–45% and occurs in 0.6% of patients with acute coronary syndromes, even with intracoronary imaging techniques [ 1 ]. High platelet counts and other factors are …

  12. 22-06-2023 | Paroxysmal Nocturnal Hemoglobinuria | Letter

    Characteristics and outcomes associated with venous thrombotic complications among patients with paroxysmal nocturnal hemoglobinuria

  13. 21-07-2023 | Paroxysmal Nocturnal Hemoglobinuria | OriginalPaper

    Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan

    Ravulizumab is a long-acting C5 inhibitor available for treating paroxysmal nocturnal hemoglobinuria (PNH). Post-marketing surveillance (PMS) was implemented following its approval in September 2019 in Japan. We report safety data obtained through …

  14. Open Access 01-12-2021 | Aplastic Anemia | OriginalPaper

    COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab

    Coronavirus disease 2019 (COVID-19) has become a global pandemic with at least 229.3 million confirmed cases and a total of 4,700,000 deaths worldwide as of September 2021 [ 1 ]. In December 2019, an outbreak of COVID-19 disease was detected in …

  15. 01-12-2021 | Thrombosis | Case Study

    JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature

    Myeloproliferative neoplasms (MPN) usually exhibit terminal myeloid cell expansion in the peripheral blood [ 1 ]. Over time, the clinical course of MPNs can be complicated with thrombosis, bleeding, and evolution to acute myeloid leukemia (AML) or …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.